Search for a trial

A Phase 1b trial in Stage II-III urothelial cancer to explore pre-operative immunotherapy - TURANDOT

We will assess feasibility of pre-operative nivolumab in PD-L1 positive resectable stage II-III urothelial cancer patients

A Phase 2 clinical study to assess efficacy of Induction ipilimumab/nivolumab to spare the Bladder in urothelial bladder cancer (IndiBlade)

This study has been transitioned to CTIS with ID 2024-512211-41-00 check the CTIS register for the current data. In this study, we investigate whether induction with immunotherapy, followed by chemoradiation as consolidative therapy is an effective…

Pre-BladParadigm - the effect of diagnostic transurethral bladder tumor resection (TURBT) on the level of circulating tumor cells (CTCs) in the blood of patients suspected of muscle invasive bladder cancer

To validate the suggestion that transurethral resection of bladder tumors in patients with suspected muscle invasive bladder cancer can lead to circulating tumor cells.

Urostoma APPtimize: Improving quality of life of patients having a urostomy by offering personalised and timed guidance and peer-contact in a patient-centred mobile application

The main objective of this study is to investigate whether quality of life can be improved by personalised and timed guidance, and/or use of the peer-support platform; as provided by a patient-centred mobile application.

A Phase III, Open Label, Randomised, 3 Arm, Multi Centre Study of Savolitinib plus Durvalumab versus Sunitinib and Durvalumab Monotherapy in Participants with MET Driven, Unresectable and Locally Advanced or Metastatic Papillary Renal Cell Carcinoma (PRCC)

This study has been transitioned to CTIS with ID 2022-503105-38-00 check the CTIS register for the current data. The purpose of this study is to assess whether a new combination treatment (Savolitinib and Durvalumab) is better than standard…

Prospective, randomized, neoadjuvant phase II study with combination immuno-oncology in primary clear cell renal cell cancer at risk for recurrence or distant metastases (NESCIO-trial; M21NSC; CA209-6DJ)

This study has been transitioned to CTIS with ID 2024-515514-40-00 check the CTIS register for the current data. The primary objective is to investigate the rate of pathological responses following different neoadjuvant immunotherapy combinations in…

A Multi-center, Double-Blind, Randomized Phase 3 Study to Compare the Efficacy and Safety of Belzutifan (MK-6482) plus Pembrolizumab (MK- 3475) Versus Placebo plus Pembrolizumab, in the Adjuvant Treatment of Clear Cell Renal Cell Carcinoma (ccRCC) Post Nephrectomy (6482-022)

This study has been transitioned to CTIS with ID 2023-505023-31-00 check the CTIS register for the current data. 1) To compare disease-free survival (DFS) as assessed by investigator for participants treated with belzutifan plus pembrolizumab versus…

A nationwide multicentre, open-label study of six months avelumab maintenance treatment in patients with locally advanced or metastatic urothelial cancer whose disease did not progress after at least 4 cycles of first-line platinum-containing chemotherapy and the opportunity to re-treat

This study has been transitioned to CTIS with ID 2024-512975-11-01 check the CTIS register for the current data. To demonstrate benefit of maintenance treatment with avelumab for a maximum of six months avelumab in increasing overall survival (OS)…

Fasting Intervention for children with Unilateral Renal Tumours to reduce Toxicity

to investigate the effect of a pre-operative fasting diet on post-operative recovery after renal tumour surgery

Individualisation of management with novel upfront therapies in newly diagnosed metastasized prostate cancer using (PSMA)PET/CT imaging

To assess the predictive value of early response measurements on PSMA-PET/CT for therapy success, defined as time to development of castration-resistant prostate cancer (CRPC), in order to personalize treatment choice.